Reviewer’s report

Title:Bortezomib and dexamethasone for multiple myeloma: AST and LDH associated with overall survival.

Version:1Date:3 April 2014

Reviewer:George Tsirakis

Reviewer's report:

In this article, there has been an effort to estimate the efficacy and safety of bortezomib+dexamethasone on pre-treated MM patients. It is a retrospective study of a small number of heterogenous patients and the major conclusion is that serum levels of AST and LDH are prognostic. I believe that, since bortezomib is first line treatment in many countries, all clinical hematologists have experience regarding its efficacy and safety. Therefore, the information provided is limited. Similarly, the prognostic impact of LDH is also proven. On the other hand, AST levels are interesting as prognostic, although authors do not provide sufficient explanation regarding this correlation.

Major revisions: I would modified the whole paper and oriented on the bad prognostic impact of AST, even after receiving bortezomib. By these means, I would tried to add more information regarding the hepatic dysfunction (probably with u/s and viral hepatitis data etc).

Level of interest:An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English:Acceptable

Statistical review:Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests.